These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 32266704

  • 1. Eptinezumab: First Approval.
    Dhillon S.
    Drugs; 2020 May; 80(7):733-739. PubMed ID: 32266704
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R, Olesen J.
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [Abstract] [Full Text] [Related]

  • 4. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC, Schwedt TJ.
    Prog Brain Res; 2020 Jun; 255():143-170. PubMed ID: 33008505
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New Insights into the Regulation of CGRP-Family Receptors.
    Gingell JJ, Hendrikse ER, Hay DL.
    Trends Pharmacol Sci; 2019 Jan; 40(1):71-83. PubMed ID: 30527443
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L, Haanes KA, Warfvinge K, Krause DN.
    Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
    [Abstract] [Full Text] [Related]

  • 13. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
    Pederson S, Biondi DM, Allan B, Cady R, Schaeffler B, Baker B, Latham J.
    Front Immunol; 2021 Jun; 12():765822. PubMed ID: 34759933
    [Abstract] [Full Text] [Related]

  • 14. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST, Wu JW.
    Prog Brain Res; 2020 Jun; 255():123-142. PubMed ID: 33008504
    [Abstract] [Full Text] [Related]

  • 15. Eptinezumab for the preventive treatment of migraine.
    Villar-Martínez MD, Moreno-Ajona D, Goadsby PJ.
    Pain Manag; 2021 Mar; 11(2):113-121. PubMed ID: 33280422
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Eptinezumab for the treatment of migraine.
    Scuteri D, Corasaniti MT, Tonin P, Bagetta G.
    Drugs Today (Barc); 2019 Nov; 55(11):695-703. PubMed ID: 31840684
    [Abstract] [Full Text] [Related]

  • 19. Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine.
    Jinesh S.
    Inflammopharmacology; 2023 Oct; 31(5):2245-2251. PubMed ID: 37421480
    [Abstract] [Full Text] [Related]

  • 20. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
    Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society.
    Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.